UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update

Journal of clinical oncology, 2021-12, Vol.39 (35), p.3959-3977

2021

Volltextzugriff (PDF)

Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium

Breast cancer research and treatment, 2020-06, Vol.181 (3), p.487-497

2020

Volltextzugriff (PDF)

Unmet challenges in systemic therapy for early stage breast cancer

Breast (Edinburgh), 2022-03, Vol.62 (Suppl 1), p.S67-S69

Burstein, Harold J.

2022

Volltextzugriff (PDF)

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

Journal of clinical oncology, 2016-09, Vol.34 (25), p.3069-3103

2016

Volltextzugriff (PDF)

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

Journal of clinical oncology, 2012-07, Vol.30 (21), p.2585-2592

2012

Volltextzugriff (PDF)

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

Journal of clinical oncology, 2010-03, Vol.28 (7), p.1124-1130

2010

Volltextzugriff (PDF)

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

Journal of clinical oncology, 2010-03, Vol.28 (8), p.1301-1307

2010

Volltextzugriff (PDF)

American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

Journal of clinical oncology, 2010-08, Vol.28 (23), p.3784-3796

2010

Volltextzugriff (PDF)

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials

Journal of clinical oncology, 2017-09, Vol.35 (27), p.3113-3122

2017

Volltextzugriff (PDF)

Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab

Journal of clinical oncology, 2011-02, Vol.29 (6), p.632-638

2011

Volltextzugriff (PDF)

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Journal of clinical oncology, 2008-04, Vol.26 (11), p.1810-1816

2008

Volltextzugriff (PDF)

Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease

Journal of clinical oncology, 2008-02, Vol.26 (5), p.814-819

2008

Volltextzugriff (PDF)

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays

Journal of clinical oncology, 2011-08, Vol.29 (24), p.3328-3330

2011

Volltextzugriff (PDF)

American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer

Journal of clinical oncology, 2005-10, Vol.23 (30), p.7703-7720

2005

Volltextzugriff (PDF)

Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Journal of clinical oncology, 2008-04, Vol.26 (12), p.1993-1999

2008

Volltextzugriff (PDF)

The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer

NPJ breast cancer, 2023-03, Vol.9 (1), p.15-15, Article 15

2023

Volltextzugriff (PDF)

Aromatase inhibitor-associated arthralgia syndrome

Breast (Edinburgh), 2007-06, Vol.16 (3), p.223-234

Burstein, Harold J

2007

Volltextzugriff (PDF)

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004

Journal of clinical oncology, 2005-01, Vol.23 (3), p.619-629

2005

Volltextzugriff (PDF)

Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review

Progress in cardiovascular diseases, 2010-09, Vol.53 (2), p.94-104

2010

Volltextzugriff (PDF)

Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Reply

The New England journal of medicine, 2021-03, Vol.384 (12), p.1176-1177

Burstein, Harold J

2021

Volltextzugriff (PDF)

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study

Cancer, 2007-09, Vol.110 (5), p.965-972

2007

Volltextzugriff (PDF)

Anthracyclines in Early Breast Cancer: The Long Goodbye

Journal of clinical oncology, 2024-11

2024

Volltextzugriff (PDF)

Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

Cancer, 2003-06, Vol.97 (12), p.2972-2977

2003

Volltextzugriff (PDF)

Escalation, De-escalation, Adaptation, Speciation, Customization: The New Approaches to Breast Cancer

Hematology/oncology clinics of North America, 2023-02, Vol.37 (1), p.xiii-xvi

Burstein, Harold J.

2023

Volltextzugriff (PDF)

Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer

Clinical cancer research, 2007-02, Vol.13 (4), p.1198-1207

2007

Volltextzugriff (PDF)

1 – 25 von 320

Suche als RSS-Feed

Aktive Filter

KollektionSAGE Journals

ThemaChemotherapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(309)
Mit Volltextzugriff
(213)

Publikationsform

Sprache

Englisch
(320)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(207)
Life Sciences & Biomedicine
(200)
Science & Technology
(200)
Oncology
(180)
Female
(161)
Breast Neoplasms - Drug Therapy
(100)
Biological And Medical Sciences
(58)
Medical Sciences
(55)
Breast Cancer
(54)
Breast Neoplasms - Pathology
(54)
Middle Aged
(53)
Tumors
(52)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(51)
Adult
(45)
Chemotherapy, Adjuvant
(44)
Aged
(43)
Breast Neoplasms - Therapy
(40)
Gynecology. Andrology. Obstetrics
(36)
Mammary Gland Diseases
(36)
Neoplasm Staging
(36)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update

Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium

Unmet challenges in systemic therapy for early stage breast cancer

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials

Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays

American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer

Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer

Aromatase inhibitor-associated arthralgia syndrome

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004

Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review

Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Reply

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study

Anthracyclines in Early Breast Cancer: The Long Goodbye

Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

Escalation, De-escalation, Adaptation, Speciation, Customization: The New Approaches to Breast Cancer

Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer

Aktive Filter

Suchergebnisse filtern